- In post-hoc analysis, the exposure-adjusted rates of all-cause death and/or hospitalization were reduced approximately 50% in patients receiving Patisiran vs placebo
- hATTR... read more
Allogene Therapeutics, Inc., a... read more
Acorda Therapeutics, Inc. (Nasdaq:ACOR)... read more
Microbiome Insights, Inc. is pleased to announce that it will receive a contribution of up to $190,249 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,